-
Product Insights
Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) - Drugs In Development, 2023’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy - Drugs In Development, 2023’, provides an overview of the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Drugs In Development, 2023’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in...
-
Product Insights
Oral Mucositis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Oral Mucositis Clinical Trial Report Overview A total of 506 Oral Mucositis clinical trials were conducted as of December 2023. The Oral Mucositis clinical trial report provides a comprehensive understanding of the Oral Mucositis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
Sonnedix Tono Solar PV Park
Sonnedix Tono Solar PV Park is a solar PV project located in Iwate, Japan. The project is owned by Sonnedix Japan KK and was developed by Sonnedix Japan KK; SunPower Corp. The project came online in 2020. Empower your strategies with our Sonnedix Tono Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...